Related Experiment Videos
[Therapy of chronic hepatitis C]
1Klinische Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin IV, Währinger Gürtel 18-20, A-1090 Wien. peter.ferenci@akh-wien.ac.at
Wiener Medizinische Wochenschrift (1946)
|February 24, 2001
Summary
Hepatitis C treatment with interferon-alpha alone has low sustained response rates. Combination therapy with ribavirin significantly improves outcomes, especially for subtype 1 and 3 infections.
Area of Science:
- Hepatology and Virology: Focuses on viral hepatitis and antiviral therapies.
Context:
- Interferon-alpha remains the sole antiviral agent for Hepatitis C Virus (HCV).
- Monotherapy with interferon-alpha yields low sustained virologic response (SVR) rates, particularly in subtype 1 patients (3-10%).
- Improved therapeutic strategies are essential for effective Hepatitis C management.
Purpose:
- To review the efficacy of interferon-alpha monotherapy and combination therapies for Hepatitis C.
- To explore potential advancements in Hepatitis C treatment.
Summary:
- Combination therapy with ribavirin represents a significant advancement, reducing relapse rates.
- Sustained response rates increased to 30% for subtype 1 and 65% for subtype 3 with combination therapy.
- Future improvements may involve high-dose induction therapy, pegylated interferons, and antifibrotic agents for nonresponders.
Impact:
- Combination therapy enhances Hepatitis C treatment efficacy, offering better SVR rates.
- Pegylated interferons and novel agents like IL-10 and silymarin show promise for further therapeutic gains.
- These advancements are crucial for improving patient outcomes in Hepatitis C infection.